期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

线粒体损伤在心肌病发病机制中的作用及干预策略 被引量：2

原文传递
导出
摘要 心肌病是儿科严重心脏疾病之一,预后差,病死率及病残率高。近二十年来,心肌病发病机制、诊断及治疗等方面研究已取得较大进展,特别是在线粒体损伤与心肌病关系方面取得了突破。线粒体损伤在心肌病发病机制中起关键作用,线粒体成为治疗心肌病的一个潜在药物靶点。
作者 周丽芳 李双杰
机构地区 湖南省儿童医院肝病中心南华大学儿科学院
出处 《中国实用儿科杂志》 CSCD 北大核心 2014年第9期666-668,共3页 Chinese Journal of Practical Pediatrics
基金 国家科技支撑计划项目(2012BAI04B00) 湖南省科技厅项目(2012TT2026)
关键词 心肌病 线粒体 发病机制 儿童
分类号 R72 [医药卫生—儿科]
  • 相关文献

参考文献22

  • 1Elliott P, Anderson B, Arbnstini E. et al.Classification of the cardiomyopathies : a position statement from the European Soci- ety of Cardiology Working Group on Myocardial and Pericardial diseases[J]. Eur Heart J,2008,29(2):270-276.
  • 2章旭,黄美蓉,陈树宝,武育蓉,柏屏,郭颖,傅立军,赵鹏军,高伟,李奋,李筠,张玉奇.儿童心肌病诊断治疗10年回顾[J].临床儿科杂志,2011,29(4):345-348. 被引量：17
  • 3Sauvanet C, Duvezin-Caubet S,di Rago JP, et al. Energetic re- quirements and bioenergetic modulation of mitochondriaI mor- phology and dynamics[J]. Semin Cell Dev Biol, 2010,21 (6) : 558-565.
  • 4Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance [J]. J Clin Invest, 2005, 115 (3) : 547-555.
  • 5Ardehali H, Sabbah HN, Burke MA, et al. Targeting myocardi- al substrate metabolism in heart failure : potential for new thera- pies[J]. EurJ Heart Fail,2012,14(2) : 120-129.
  • 6朱业,顾翔.线粒体DNA与心肌病的关系[J].中华老年多器官疾病杂志,2012,11(6):473-476. 被引量：3
  • 7Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy [J]. Prog Pediatr Cardiol, 2007,24( 1 ) : 15-25.
  • 8Thebault C, Ollivier R, Leurent G, et al. Mitochondriopathy: a rare aetiology of restrictive cardiomyopathy [J]. Eur J Echocar- diogr, 2008,9 (6) : 840-845.
  • 9Zaragoza MV, Brandon MC, Diegoli M, et al. Mitochondrial cardiomyopathies: how to identify candidate pathogenic muta- tions by mitochondrial DNA sequencing, MITOMASTER and phylogeny[J]. Ear J Hum Genet,2011,19(2):200-207.
  • 10阿力木江.买买提江,高秀芳,金波,施海明.线粒体动力学与心肌细胞能量代谢的研究进展[J].复旦学报（医学版）,2013,40(5):625-628. 被引量：11

二级参考文献75

  • 1Konia MR,Schaefer S,Liu H.Nuclear factor-[kappa] B inhibition provides additional protection against ischaemia/reperfusion injury in delayed sevoflurane preconditioning.Eur J Anaesthesiol,2009,26(6):496-503.
  • 2Mullenheim J,Ebel D,Bauer M,et al.Sevoflurane confers additional cardioprotection after ischemic late preconditioning in rabbits.Anesthesiology,2003,99(3):624-631.
  • 3Pravdic D,Sedlic F,Mio Y,et al.Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein Kinase C-epsilon-mediated pathway.Anesthesiology,2009,111(2):267-274.
  • 4Yao YT,Li LH,Chen L,et al.Sevoflurane postconditioning protects isolated rat hearts against ischemia-reperfusion injury:the role of radical oxygen species,extracellular signal-related kinases 1/2 and mitochondrial permeability transition pore.Mol Biol Rep,2010,37(5):2439-2446.
  • 5Chen CH,Chuang JH,Liu K,et al.Nitric oxide triggers delayed anesthetic preconditioning-induced cardiac protection via activation of nuclear factor-kappaB and upregulation of inducible nitric oxide synthase.Shock,2008,30(3):241-249.
  • 6Bolli R.Preconditioning:a paradigm shift in the biology of myocardial ischemia.Am J Physiol Heart Circ Physiol,2007,292(1):19-27.
  • 7Halestrap AP.What is the mitochondrial permeability transition pore?J Mol Cell Cardiol,2009,46(6):821-831.
  • 8Malekova L,Kominkova V,Ferko M,et al.Bongkrekic acid and atractyloside inhibits chloride channels from mitochondrial membranes of rat heart.Biochim Biophys Acta,2007,1767(1):31-44.
  • 9Gross ER,Hsu AK,Gross GJ.Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP-and MPTP-dependent mechanism at reperfusion.Am J Physiol Heart Circ Physiol,2008,294(3):H1497-1500.
  • 10Xu M,Wang Y,Hirai K,et al.Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis.Am J Physiol Heart Circ Physiol,2001,280(2):H899-H908.

共引文献35

同被引文献26

  • 1齐建光,张英,戚豫,杨艳玲,吴晔,姜玉武,秦炯,杜军保.儿童线粒体病心脏损害23例临床分析[J].实用儿科临床杂志,2006,21(1):12-13. 被引量：10
  • 2Nugent TW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia [J]. N Engl J Med , 2003,348(17) : 1639-1646.
  • 3Lipshultz SE, Sleeper L, Towbin JA, et al. The incidence of pedi- atric cardiomyopathy in two region of the United States [J]. N Engl J Med, 2003,348 : 1647-1655.
  • 4Kaski JP, Syrris P, Esteben MTT, et al. Prevalence of sareomere protein gene mutation in preadolescent children with HCM [J]. Cire Cardiovasc Genet, 2009,2 (5) : 436-441.
  • 5Morita H, Rehm H, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults [J]. N Engl J Med, 2008,358(18) : 1899-1908.
  • 6Wheeler M, Pavlovie A, DeGoma E, et al. A new era in clinical genetic testing for hypertrophic cardiomyopathy [J]. J Cardio- vase Transl Res ,2009,2(4):381-391.
  • 7Ghosh N, Haddad H. Recent progress in the genetics of eardio- myopathy and its role in the clinical evaluation of patients with cardiomyopathy [J]. Curt Opin Cardiol, 2011, 26 (2) : 155- 164.
  • 8Marian AJ. Hypertrophic cardiomyopathy : from genetics to tat- ment[J]. EurJ Clin Invest,2010,40(4) : 360-369.
  • 9Hersberger RE, Cowan J, Morales A, et al. Progress with genetic cardiomyopathies [J]. Circ Heart fail, 2009,2 : 253-261.
  • 10Hershberger RE, Siegfried JD. Update 2011: clinical and ge- netic issues in familial dilated cardiomyopathy[ J]. J Am Coil Cardiol, 2011,57(16) : 1641-1649.

引证文献2

二级引证文献4

中国实用儿科杂志
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部